Gender features of malignant neoplasms associated with human papillo-mavirus in St. Petersburg

Abstract

Objective.To study the peculiarities of morbidity and mortality from malignant neoplasms associated with the human papillomavirus among male and female population in a megalopolis. The International Agency for Research on Cancer relates cancer of the oral cavity, tonsils and oropharynx, larynx, anal canal and skin of the perianal region, vulva, vagina, cervix and penis to malignant neoplasms associated with the human papillomavirus.

Material and methods. The analysis of morbidity and mortality was carried out according to the Population Cancer Registry of St. Petersburg for the period 2011–2020. The structure of the localization of the tumor process, trends and levels of morbidity and mortality from neoplasia associated with papillomavirus infection were studied. The study included information on 13,117 cases of the disease and 7,257 deaths.

Research methods: epidemiological, clinical, statistical methods.

Results. Among all the malignant neoplasms, the proportion of HPV-associated neoplasias was 5.1 % in men and 5.8 % in women (p < 0.05). In the structure of morbidity and mortality from HPV-associated tumors, cancer of the oral cavity and larynx occupies the largest share among men, and cervical cancer among women. The incidence of oropharyngeal cancer among the male population is higher compared to the female, the incidence of anal cancer among women is 2.9 times higher and there is an upward trend with higher growth rates (p < 0.05).

Conclusions. The established gender differences of HPV-associated malignant neoplasms should be taken into account when justifying the directions for improving dispensary monitoring of patients and vaccination of papillomavirus infection.

Keywords

malignant neoplasms associated with human papillomavirus / morbidity / mortality / gender differences

References

[1] Wild C.P., Weiderpass E., Stewart B.W., editors (2020). World Cancer Report: Cancer Research for Cancer Prevention. Lyon, France: International Agency for Research on Cancer, available at: http://www.publications.iarc.fr/586.

[2] Bruni L., Albero G., Serrano B. et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report. 2022.

[3] Bruni L., Albero G., Serrano B. et al. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in the World. Summary Report 2022.

[4] de Martel C., Plummer M., Vignat J. et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017; 141 (4): 664–670.

[5] Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021; 71 (3): 209–249.

[6] Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021; 71 (3): 209–249.

[7] Gretsova O.P., Kostin A.A., Samsonov Yu.V. et al. Morbidity and mortality from malignant neoplasms associated with human papillomavirus. Research’n Practical Medicine Journal. 2017; 4 (3): 33–50 (in Russan).

[8] Грецова О.П., Костин А.А., Самсонов Ю.В, и др. Заболеваемость и смертность от злокачественных новообразований, ассоциированных с вирусом папилломы человека. Research'n Practical Medicine Journal 2017; 4 (3): 33–50.

[9] Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: P. Hertsen MORI – branch of the FSBI NMRRC of the Ministry of Health of the Russian Federation 2021; 252 (in Russan).

[10] Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России 2021; 252.

[11] Arbyn M., Weiderpass E., Bruni L. et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020; 8 (2): 191–203.

[12] Vaginal cancer incidence statistics. Cancer Research UK. 2020, available at: https:// www.cancerresearchuk.org/health-professional/ cancer-statistics/statistics-by-cancer-type/vaginal-cancer/incidence#heading-One.

[13] Vaginal cancer incidence statistics. Cancer Research UK. 2020, available at: https: //www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ vaginal-cancer/incidence#heading-One.

[14] Worldwide cancer data, 2020. World Cancer Research Fund International. 2020, available at: https://www.wcrf.org/dietandcancer/worldwide-cancer-data.

[15] Heer E., Hackl M., Et M. et al. Trends in incidence of anal cancer in Austria, 1983–2016. Wien Klin Wochenschr. 2020; 132 (15): 438–443.

[16] Heer E., Hackl M., Et M. et al. Trends in incidence of anal cancer in Austria, 1983–2016. Wien Klin Wochenschr 2020; 132 (15): 438–443.

[17] Hansen B.T., Orumaa M., Lie A.K., Brennhovd B., Nygård M. Trends in incidence, mortality and survival of penile squamous cell carcinoma in Norway 1956–2015. Int J Cancer. 2018; 142 (8): 1586–1593.

[18] Cancer Stat Facts: Oral Cavity and Pharynx Cancer. Surveillance, Epidemiology, and End Results Programe 18, 2010–2016. National Cancer Institute, 2018, available at: https://www. seer.cancer.gov/statfacts/html/oralcav.html.

[19] Cancer Stat Facts: Oral Cavity and Pharynx Cancer. Surveillance, Epidemiology, and End Results Programe 18, 2010–2016. National Cancer Institute 2018, available at: https:// www.seer.cancer.gov/statfacts/html/oralcav.html.

[20] Perea L.M., Estrada Peres M.A., Boing A. Fernando, et al. Trend of oral and pharyngeal cancer mortality in Brazil in the period of 2002 to 2013. Rev. Saúde Pública. 2018; 52.

[21] Perea, L.M. Estrada, Peres M.A., Boing A. Fernando, et al. Trend of oral and pharyngeal cancer mortality in Brazil in the period of 2002 to 2013. Rev. Saúde Pública 2018; 52.

[22] Nelson V.M., Benson A.B., 3rd. Epidemiology of Anal Canal Cancer. Surg Oncol Clin N Am. 2017; 26 (1): 9–15.

[23] Nelson V.M., Benson A.B. Epidemiology of Anal Canal Cancer. Surg Oncol Clin N Am. 2017; 26 (1): 9–15.

[24] Mensah F.A., Mehta M.R., Lewis J.S., Jr., et al. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal Intraepithelial neoplasia and anal cancer. Oncologist. 2016; 21 (4): 453–460.

[25] Mensah F.A., Mehta M.R., Lewis J.S., Jr., et al. The human papillomavirus vaccine: current perspective and future role in prevention and treatment of anal Intraepithelial neoplasia and anal cancer. Oncologist. 2016; 21 (4): 453–460.

[26] Briko N.I., Lopukhov P.D., Kaprin A.D., et al. HPV-associated lesions in the Russian Federation: assessment of the problem. Journal of Modern Oncology. 2019; 21 (1): 45–50 (in Russan).

[27] Лялина Л.В. Эпидемиологическое, социальное и экономическое обоснование вакцинации против папилломавирусной инфекции в Санкт-Петербурге. Инфекц. и иммунитет. 2014; 4 (2): 181–186.

[28] Lyalina L.V. Epidemiological, social and economic evidences of vaccination against human papillomavirus infection in Saint-Petersburg. Infektsiya i immunitet = Russian Journal of Infection and Immunity. 2014; 4 (2): 181–186 (in Russan).

[29] Брико Н.И., Лопухов П.Д., Каприн А.Д. и др. ВПЧ-ассоцированные поражения в Российской Федерации: оценка состояния проблемы. Современная онкология. 2019; 21 (1): 45–50.

RIGHTS & PERMISSIONS

Lyalina L.V., Kholopov D.V., Khizha V.V., Kasatkin E.V., Topuzov Е.Е.